STING1 and breast cancer: Because the preclinical efficacy associated with intratumoral injection of a STING agonist may be difficult to translate to a heterogenous metastatic BC, it will be important to extend these findings to other tumor models and to determine whether similar results can be achieved with systemic agonists of STING, currently under development19,20.